Overview

A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)

Status:
Completed

Trial end date:
2009-05-31

Target enrollment:

Participant gender:

Summary

This open label 52-week clinical trial is designed to assess the safety and tolerability of vilazodone and to analyze genetic markers of response to vilazodone in adult patients diagnosed with MDD. This study will enroll approximately 600 patients.

Phase:

Phase 3

Details

Lead Sponsor:

Forest Laboratories

Treatments:

Vilazodone Hydrochloride